Cancer therapy has remarkable potential for drug-related problems due to the high cytotoxicity and narrow therapeutic index of most anti-neoplastic regimens. However, there is a lack of comprehensive studies on drug-related problems in patients with gastrointestinal cancer in Kenya. Therefore, the present study aimed to investigate the prevalence, types and predictors of drug-related problems among gastrointestinal cancer patients at Kenyatta National Hospital.
Methods
A cross-sectional study was used to assess the prevalence of drug-related problems among a random sample of 160 esophageal, 103 gastric, and 96 colorectal cancer patients. Data were collected using a researcher-administered questionnaire and data abstraction tool after training the data collectors. Patient-specific details such as socio-demographic features, histological cancer types, cancer stage, comorbidity types, and treatment regimen were recorded after the review of medical records and patient interviews. The potential of drug-related problems was determined as per the standard guidelines. The data were entered and analysed using version 26.0 SPSS statistical software.
Results
Most esophageal (51.9%), gastric (59.2%), and colorectal (62.5%) cancer patients had a high prevalence of drug-related problems. The need for additional drug therapy and adverse drug reactions were the predominant categories of drug-related problems. Most adverse drug reactions identified had possible categories of causality score, mild severity levels, and definitely preventable types of adverse drug reactions among all gastrointestinal cancer patients. Comorbidity and advanced-stage disease were significant predictors of drug-related problems.
Conclusions
Drug-related problems were prevalent among gastrointestinal cancer patients in our setting. Comorbidity and advanced stages of disease were significant predictors of drug-related problems.
RuthsSViktilKKBlixHS. Classification of drug-related problems. Tidsskr Nor Laegeforen2007; 127: 3073–3076.
3.
NiXFYangCSBaiYM, et al.Drug-Related problems of patients in primary health care institutions: A systematic review. Front Pharmacol2021; 12: 1813.
4.
AyalewMBTegegnHGAbdelaOA. Drug related hospital admissions; A systematic review of the recent literatures. Bull Emerg Trauma2019; 7: 339.
5.
LimREllettLMKSempleS,et al.The extent of medication-related hospital admissions in Australia: A review from 1988 to 2021. Drug Saf2022; 45: 249–257.
6.
DemessieMBBerhaAB. Prevalence and predictors of drug-related hospitalisation among patients visiting emergency departments of Addis Ababa city hospitals in Ethiopia: A multicentre prospective observational study. BMJ Open2022; 12: e054778.
7.
KemalLKShewagaTGSemaFD. Drug-Related hospital admissions and associated factors among adults admitted to Felege Hiwot comprehensive and specialized hospital, North West Ethiopia. J Environ Public Health2022; 2022: 6767488.
8.
ZhangJXuRZhaoX, et al.The effectiveness of an independent anti-neoplastic medication therapy management system in ambulatory cancer patients. Transl Cancer Res2021; 10: 1703–1711.
9.
ChanASohDKoY, et al.Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients. Support Care Cancer2014; 22: 1875–1881.
10.
VandykADHarrisonMBMacArtneyG, et al.Emergency department visits for symptoms experienced by oncology patients: a systematic review. Support Care Cancer2012; 20: 1589–1599.
11.
LundJLSanoffHKHintonSP, et al.Potential medication-related problems in older breast, colon, and lung cancer patients in the United States. Cancer Epidemiol Biomarkers Prev2018; 27: 41–49.
12.
RamasubbuSKMahatoSKAgnihotriA, et al.Prevalence, severity, and nature of risk factors associated with drug-drug interactions in geriatric patients receiving cancer chemotherapy: a prospective study in a tertiary care teaching hospital. Cancer Treat Res Commun2021; 26: 100277.
13.
CipolleRStrandLMorleyP. Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management Services. 3rd ed. USA: McGraw-Hill Education, 2012.
14.
KoYGweeYSHuangYC, et al.Costs and length of stay of drug-related hospital admissions in cancer patients. Clin Ther2014; 36: 588–592.
15.
PattanaikSDhamijaPMalhotraS, et al.Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in northern India: A prospective study. Br J Clin Pharmacol2009; 67: 363.
16.
FreitasGdTramontinaMYBalbinottoG, et al.Economic impact of emergency visits due to drug-related morbidity on a Brazilian hospital. Value Heal Reg Issues2017; 14: 1–8.
17.
MathewEThava PriyaCSAdityaSA, et al.Cost analysis of emergency visits due to drug related problems. Int J Pharm Pharm Sci2019; 11: 35–38.
18.
BulsinkAImholzALTBrouwersJRBJ,et al.Characteristics of potential drug-related problems among oncology patients. Int J Clin Pharm2013; 35: 401–407.
19.
CehajicIBerganSBjordalK. Pharmacist assessment of drug-related problems on an oncology ward. Eur J Hosp Pharm2015; 22: 194–197.
20.
IftikharAJehanzebKUllahA. Clinical pharmacy services in medical oncology unit, Peshawar, Pakistan. Pharmacologyonline2015; 1: 10–12.
21.
VersteegKSKoningsIRLagaayAM, et al.Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: A systematic review. Ann Oncol2014; 25: 1914–1918.
22.
JaehdeULiekwegASimonsS,et al.Minimising treatment-associated risks in systemic cancer therapy. Pharm World Sci2008; 30: 161–168.
23.
SisayEAEngidaworkEYesufTA,et al.Drug related problems in chemotherapy of cancer patients. J Cancer Sci Ther2015; 07: 55–59.
24.
DeguANjoguPWeruI,et al.Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya. Gynecol Oncol Res Pract2017; 4: 15.
25.
KohYKuttyFBLiSC. Drug-related problems in hospitalised patients on polypharmacy: the influence of age and gender. Ther Clin Risk Manag2005; 1: 39–48.
26.
KasiuleviciusVSapokaVFilipaviciuteR. Sample size calculation in epidemiological studies. Gerontologija2006; 7: 225–231.
27.
NaranjoCABustoUSellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
28.
HartwigSCSiegelJSchneiderPJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm1992; 49: 2229–2232.
29.
SchumockGTThorntonJP. Focusing on the preventability of adverse drug reactions. Hosp Pharm1992; 27: 538.
BensonABVenookAPCederquistL, et al.Colon cancer, version 1.2017: Clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw2017; 15: 370–398.
32.
BensonABVenookAPAl-HawaryMM, et al.Rectal cancer, version 2.2018 clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw2018; 16: 874–901.
33.
AjaniJAD’AmicoTAAlmhannaK, et al.Gastric cancer, version 3.2016; clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw2016; 14: 1286–1312.
34.
AjaniJAD’AmicoTABentremDJ, et al.Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw2019; 17: 855–883.
35.
BulsinkAImholzALBrouwersJR,et al.Characteristics of potential drug-related problems among oncology patients. Int J Clin Pharm2013; 35: 401–407.
36.
OčovskáZMaříkováMKočíJ,et al.Drug-Related hospital admissions via the department of emergency medicine: a cross-sectional study from the Czech Republic. Front Pharmacol2022 Jun 13; 13: 899151.
37.
AyalewMBTegegnHGAbdelaO. Drug related hospital admissions; A systematic review of the recent literatures. Bull Emerg Trauma2019; 7: 339–346.
38.
SisayEAEngidaworkEYesufTA,et al.Drug related problems in chemotherapy of cancer patients. J Cancer Sci Ther2015; 7: 2.
39.
DeguAKebedeK. Drug-related problems and its associated factors among breast cancer patients at the University of Gondar Comprehensive Specialized Hospital, Ethiopia: A hospital-based retrospective cross-sectional study. J Oncol Pharm Pract2021 Jan 6; 27: 88–98.
40.
KefaleBEngidawMTTesfaD, et al.Management practice and drug related problems and its contributing factors among cervical cancer patients at oncologic center in Ethiopia: A hospital-based retrospective study. Ther Clin Risk Manag2022 Jun; 18: 643–655.
41.
KefaleBEngidawMTTesfaD, et al.Clinical pattern and drug-related problems among colorectal cancer patients at oncology center in Ethiopia: A hospital-based study. SAGE open Med2022; 10: 205031212211316.
42.
TezcanSİzzettinFVSancarM, et al.Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer. Eur J Hosp Pharm2018 Mar; 25: e17–e20.
43.
IslamiFGoding SauerAMillerKD, et al.Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin2018 Jan; 68: 31–54.
44.
LundJLSanoffHKHintonSP, et al.Potential medication-related problems in older breast, colon, and lung cancer patients in the United States. Cancer Epidemiol Biomarkers Prev2018; 27: 41–49.
45.
KinironsMTO'MahonyMS. Drug metabolism and ageing. Br J Clin Pharmacol2004 May; 57: 540–544.
46.
MangoniAAJacksonSHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol2003 Nov 14; 57: 6–14.
47.
RejiRKumarBSreedharanN, et al.Evaluation of supportive care management outcomes in cancer chemotherapy: A prospective observational study in a tertiary care teaching hospital in south India. Indian J Palliat Care2018; 24: 179.
48.
YeohTTTayXYSiP,et al.Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy. J Geriatr Oncol2015; 6: 280–287.
49.
RiechelmannRPKrzyzanowskaMK. Drug interactions and oncological outcomes: A hidden adversary. Ecancermedicalscience2019 Mar 28; 13: ed88.
50.
van LeeuwenRWBrundelDHNeefC, et al.Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer2013; 108: 1071–1078.
51.
WangWXiaoBLiuZ, et al.The prevalence of the potential drug-drug interactions involving anticancer drugs in China: A retrospective study. Iran J Public Health2019 May 15; 48: 435–443.
52.
Turossi-AmorimEDCamargoBSchuelter-TrevisolF. Prevalence of potential pharmacological interactions in patients undergoing systemic chemotherapy in a tertiary hospital. Hosp Pharm2022 Oct 2; 57: 646–653.
53.
RamasubbuSPasrichaRNathU,et al.Frequency, nature, severity and preventability of adverse drug reactions arising from cancer chemotherapy in a teaching hospital. J Fam Med Prim Care2020; 9: 3349.
54.
SainiVSewalRAhmadY,et al.Prospective observational study of adverse drug reactions of anticancer drugs used in cancer treatment in a tertiary care hospital. Indian J Pharm Sci2015; 77: 687.
55.
WorkalemahuGAbdelaOAYenitMK. Chemotherapy-Related adverse drug reaction and associated factors among hospitalised paediatric cancer patients at hospitals in north-west Ethiopia. Drug Healthc Patient Saf2020 Nov; 12: 195–205.
56.
MonestimeSPageRJordanWM,et al.Prevalence and predictors of patients reporting adverse drug reactions to health care providers during oral targeted cancer treatment. J Am Pharm Assoc2021 Jan; 61: 53–59.
57.
KrishnarajanDSivasakthiKAriyamolR, et al.A prospective observational study of chemotherapy-induced adverse drug reaction and the quality of life in cancer patients in a tertiary care hospital. J Cancer Res Ther2021; 17: 530.
58.
VargheseJMatetiUShettyJ, et al.Incidence and cost of chemotherapy-induced adverse drug reactions among cancer patients in a charitable hospital. J Reports Pharm Sci2021; 10: 110.
59.
BelachewSAErkuDAMekuriaAB,et al.Pattern of chemotherapy-related adverse effects among adult cancer patients treated at gondar university referral hospital, Ethiopia : a cross- sectional study. Drug Heal Patient Saf2016; 8: 83–90.
60.
ChopraDRehanHSSharmaV,et al.Chemotherapy-induced adverse drug reactions in oncology patients: a prospective observational survey. Indian J Med Paediatr Oncol2016; 37: 42–46.
61.
TamangRBharatiLKhatiwadaAP, et al.Pattern of adverse drug reactions associated with the use of anticancer drugs in an oncology-based hospital of Nepal. JMA J2022; 5: 416–426.
62.
LavanAHO'MahonyDBuckleyM, et al.Adverse drug reactions in an oncological population: prevalence, predictability, and preventability. Oncologist2019 Sep 1; 24: e968–e977.
63.
WahlangJBLaishramPDBrahmaDK, et al.Adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital. Ther Adv Drug Saf2017; 8: 61–66.
64.
SinghSSinghP. Pattern and impact of drugs targeted toward toxicity amelioration in patients receiving cancer chemotherapy. Perspect Clin Res2018; 9: 23.
65.
SharmaPMisraAGuptaA, et al.A retrospective analysis of reporting of adverse drug reactions to oncology drugs: an experience from a national center of clinical excellence. Indian J Pharmacol2018; 50: 273.
66.
SinghSDhasmanaDCBishtM,et al.Pattern of adverse drug reactions to anticancer drugs : a quantitative and qualitative analysis. Indian J Med Paediatr Onco2017; 38: 140–145.
67.
ThakurRBajajJKDuttaA,et al.Retrospective observational study to evaluate causality, preventability and severity of adverse drug reaction associated with anticancer drugs in a tertiary care hospital in Northern India. Curr Drug Saf2022 Nov; 17: 335–343.
68.
SisayEAEngidaworkEYesufTA,et al.Drug related problems in chemotherapy of cancer patients. J Cancer Sci Ther2015; 7: 55–59.
